Abatacept is considered for payment in the following indications:
Adults with rheumatoid arthritis (RA) age 18 or older when the patient has had inadequate response after three months in treatment with any of the following:
a. Inhibitors of the tumor necrosis factor (etanercept, infliximab, adalimumab, antagonists of the receiver of Interleukin-1)
b. Non biological Disease modifying anti-rheumatic drugs (DMARDs) (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide).
Moderate to severe Juvenile Idiopathic Arthritis (JIA) in children ≥ 2 years of age, as monotherapy or in combination with methotrexate
Active Psoriatic Arthritis (PsA)
Rheumatoid lung disease with rheumatoid arthritis
Rheumatoid arthritis with rheumatoid factor, unspecified
Orencia may be considered investigational for all other ages and indications.